Abstract:Vascular endothelial growth factor receptor-2 (VEGFR-2) has been shown to play a major role in inducing the full spectrum of VEGF biological response which is essential for tumor angiogenesis. We have demonstrated that immunotherapy of tumors with a vaccine based on quail homologous VEGFR-2 (qVEGFR) was effective in providing both protective and therapeutic antitumor immunity in several tumor models in mice. The purpose of this study was to determine whether the combination therapy of low-dose gemcitabine with qVEGFR as a vaccine could inhibit tumor growth to a greater extent. To test this concept, H22 hepatoma and Lewis lung carcinoma models were established in BALB/c mice and C57BL/6 mice, respectively. Mice were treated with either qVEGFR as a protein vaccine, gemcitabine, or both agents together. qVEGFR or low-dose chemotherapy treatment individuallyresulted in tumor inhibition to a certain extent.Remarkably, the combination therapy resulted in synergistic antitumor activity. Histological examination revealed that there was endothelial deposition of immunoglobulins within tumor tissues from mice treated with vaccine or combination therapy, especially intratumor angiogenesis was suppressed more significantly for the combination group. Also, ELISPOT analysis showed that mice treated with either qVEGFR alone or in combination with low-dose chemotherapy produced similar amount of anti-VEGFR antibody-producing B cells, which suggested that low-dose gemcitabine did not suppress the host’s immune response, but potentiated the antitumor activity of the qVEGFR vaccine. Furthermore, TUNEL staining demonstrated a significant increase in the number of TUNEL-positive cells in the combination group compared with those of other groups. The observations may provide a new bio-chemotherapeutic approach for cancer.

A Promising New Approach of VEGFR2-based DNA Vaccine for Tumor Immunotherapy.

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Immunotherapy effect on tumor and recombination of VGFR phage vaccine

[Anti-Tumor Effects Induced by the DNA Vaccine Coding Human and Mouse Soluble VEGFR2].

Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway.

Designable Immune Therapeutical Vaccine System Based on DNA Supramolecular Hydrogels.

Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models

Inhibition of Tumor Angiogenesis in Lung Cancer by T4 Phage Surface Displaying Mvegfr2 Vaccine

AN ANTI-TUMOR RESEARCH OF RECOMBINANT PHAGE VACCINE EXPRESSED XENOGENIC EGFR

Immunotherapy Of Tumors With Vaccine Based On Quail Homologous Vascular Endothelial Growth Factor Receptor-2

Immunotherapy of EGFR-positive Tumor Based on Recombinant EGFR Phage Vaccine

Combination of Low-Dose Gemcitabine and Recombinant Quail Vascular Endothelial Growth Factor Receptor-2 As a Vaccine Induces Synergistic Antitumor Activities

[Immunotherapeutic Effect of Recombinant EGFR Phage Vaccine on Tumors].

Immunogenicity and Efficacy of a Rationally Designed Vaccine Against Vascular Endothelial Growth Factor in Mouse Solid Tumor Models

VEGFR2-targeted antibody fused with IFN mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity

Active Immunotherapy for Mouse Breast Cancer with Irradiated Whole-Cell Vaccine Expressing VEGFR2.

Constructing Tumor Vaccines Targeting for Vascular Endothelial Growth Factor (vegf) by Dna Shuffling

Enhancement of Antitumor Immunity Using a DNA-based Replicon Vaccine Derived from Semliki Forest Virus.

VEGFR2-targeted Antibody Fused with IFNαmut Regulates the Tumor Microenvironment of Colorectal Cancer and Exhibits Potent Anti-Tumor and Anti-Metastasis Activity

Immunotherapy of Angiogenesis with DNA Vaccines

Induction of Protective and Therapeutic Antitumor Immunity by a DNA Vaccine with C3d As a Molecular Adjuvant